$LENZ News

Piper Sandler Maintains Neutral on LENZ Therapeutics, Lowers Price Target to $7

LENZ Therapeutics, Inc. (LENZ) Q2 2026 Earnings Call Transcript

LENZ Therapeutics Q2 EPS $(1.02) Beats $(1.06) Estimate, Sales $5.486M Beat $2.373M Estimate

LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026

LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia

LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New Zealand

LENZ Therapeutics adds China partner for presbyopia drug VIZZ

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

LENZ Therapeutics, Inc. Q1 2026 Earnings Call Summary

LENZ Therapeutics Inc (LENZ) Q1 2026 Earnings Call Highlights: Strong Prescription Growth Amid ...

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38